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Microsatellite instability (MSI-H) induced by defects of the DNA mismatch repair system results in insertion or deletion of
single nucleotides at short repetitive DNA sequences. About 15% of sporadic and approximately 90% of hereditary nonpolyposis
colorectal cancers display MSI-H. When aﬀecting coding regions, MSI-H results in frameshift mutations and expression of
corresponding frameshift peptides (FSPs). Functional tumor promoting relevance has been demonstrated for a growing number
of genes frequently hit by MSI-H. Contrary, immune reactions against FSPs are involved in the immune surveillance of MSI-H
cancers. Here, we provide conclusive data that the (−1) frame of U79260(FTO) encodes an HLA-A0201-restricted cytotoxic T cell
epitope (FSP11; TLSPGWSAV). T cells speciﬁc for FSP11 eﬃciently recognized HLA-A0201(pos) tumor cells harboring the mutated
reading frame. Considering the exceptionally high mutation rate of U79260(FTO) in MSI-H colorectal carcinoma (81.8%), this
recommends that FSP11 be a component of future vaccines.
1.Introduction
Loss of genomic stability is the key molecular step in cancer
formation [1]. Virtually all colon cancers display either
chromosome instability (CIN) or microsatellite instability
(MSI-H) indicating that genomic instability is central to
colon cancer formation. In hereditary colorectal cancer
syndromes, germline forms of key genetic defects have been
identiﬁed whose somatic occurrences drive the emergence
of sporadic colon tumors [2]. Inactivation of the DNA
mismatch repair system (MMR) due to germline defects
causes the hereditary nonpolyposis colon cancer syndrome
(HNPCC). Somatic inactivation of the MMR system due to
methylation of the promoter of hMLH1 additionally gives
risetoabout15%ofsporadiccolontumors[3].Theresulting
colon cancers display the phenotype of MSI-H recognized
as length variations in short repetitive DNA sequences called
microsatellites.
Instability of microsatellites in coding regions results in
frameshift mutations preceding expression of C-terminally
truncated proteins with attached neopeptide tails. Several
genes known to play important roles in colorectal carcino-
genesis as, for example, TGFbetaRII, Bax, AIM2, and TCF-
4 are targeted by this mutational mechanism, leading to
the hypothesis that these truncated gene products have an
impaired function and might thereby contribute to MSI-H-
driven carcinogenesis [4–7]. Several investigators have aimed
to identify other commonly mutated coding microsatellites
(cMS) in MSI-H tumors, and as a result of these eﬀorts,
numerous candidates have been identiﬁed with varying
mutation frequencies [8–10].
In any case, following proteasomal degradation, parts of
these novel proteins might be presented as immunogenic
neopeptides in the context of MHC molecules at the surface
of MSI-H cancer cells, thereby allowing for recognition of
frameshift-derived nonself by eﬀector cells of the immune
system. Several features of MSI-H tumors such as enhanced
lymphocytic inﬁltration, Crohn’s-like reactions, high preva-
lence of activated intraepithelial cytotoxic T lymphocytes,
andincreasedneoplasticcellapoptosisargueforthepresence
of an antitumoral immune reaction directed against potent
tumor rejection antigens [11–14].2 Journal of Biomedicine and Biotechnology
Thus far, we and others demonstrated the immunogenic-
ity of (−1) frameshift mutations in coding microsatellites
of TGFbRII, OGT, and Caspase-5 [15–19]. These data
established cMSI-induced frameshift-derived neopeptides
as a novel class of tumor-associated antigens likely to
represent main targets of MSI-H tumor-speciﬁc immune
reactions. In support of this hypothesis, Tougeron et al.
demonstrated a close correlation between tumor-inﬁltrating
lymphocytes and the expression of frameshift mutations
in MSI-H CRC tumors [20]. Finally, we were able to
show that T cells speciﬁc for MSI-H-induced frameshift
mutation can regularly be found in the peripheral blood
of HNPCC mutation carriers [21]. This latter ﬁnding
was independent from the actual presence of a diagnos-
able tumor. Considering the high speciﬁcity of frameshift
peptides for MSI-H tumor cells or precursors thereof,
they are most likely very interesting targets for usage in
speciﬁc antitumoral immunotherapy. So far, the number
of identiﬁed frameshift-derived T cell epitopes is very
limited. However, for creation of successful vaccines it
seems reasonable to combine several epitopes derived from
diﬀerent antigens. Therefore, it is imperative to identify
more such peptide sequences able to induce a potent T cell
response.
In the present study we characterized the immunogenic
potential of the HLA-A0201-restricted frameshift peptide
(FSP)11 (TLSPGWSAV) derived from the fat mass and
obesity-associated gene U79260(FTO).T h i sg e n ei sl o c a t e d
on chromosome 16q12.2 (gi:1710215). The function of the
gene product is still unknown, but as the name implies,
it seems to be involved in energy metabolism (reviewed
in [22]). The mRNA shows a very high mutation rate of
81.8% in colon carcinomas and up to 100% in established
colorectal carcinoma cell cultures as opposed to 6.7% in
stomach and 41.7% in endometrial carcinomas, indicating
a high speciﬁcity for colorectal cancer cells (summarized in
[23]).
2.MaterialandMethods
2.1. Tumor Cell Lines and Peptides. All tumor cell lines used
inthepresentstudy(Colo60H,HLA-0201(pos)/U79260(FTO)
(−3); HCT116, HLA-0201(pos)/U79260(FTO) (−4); SW480:
HLA-0201(pos)/U79260(FTO) (wt); and KM12: HLA-
0201(neg)/U79260(FTO) (−4)) were obtained from ATCC,
CLS (Heidelberg, Germany), or from the German Cancer
ResearchCenter(DKFZ).TheyweregrowninDMEM/Ham’s
F-12 (1 : 1) medium supplemented with 10% fetal bovine
serum (FCS), 2mmol/l glutamine, and antibiotics unless
stated otherwise. The HLA-A0201 expressing cell line T2
(174 × CEM.T2 hybridoma, TAP1, and TAP2 deﬁcient)
was used in some experiments. All media and supplements
were obtained from PAA (Coelbe, Germany) unless stated
otherwise.
Peptide FSP11 derived from the (−1)-mutated form
of U79260(FTO) (TLSPGWSAV; gi:1710215) and control
peptide(MP:GILGLVFVTL)wereobtainedfromthePeptide
Synthesis Facility of the DKFZ. They were dissolved in
DMSO (5 mg/ml) and further diluted in PBS (500μg/mL).
2.2.GenerationofCD40-ActivatedBCellsandPeptide-Speciﬁc
Stimulation of T Cells. Peripheral blood was obtained from
a healthy HLA-0201(pos) donor after informed consent in
written form was obtained. The experiments were approved
by the responsible Ethical Committee. B and T cells were
puriﬁed as described in detail before [15]. B cells were
stimulated via NIH/3T3 ﬁbroblasts stably expressing human
CD154(t-CD154).Lethallyirradiated(60Gy)t-CD154were
plated on 6-well plates (0.4 × 105 cells/well) and cultured
overnight.AfterrinsingwithPBS,theBcellswereadded(1 ×
106 cells/well) in medium containing 10% FCS, 2mmol/l
glutamine, supplements (1 : 100), and IL-4 (2ng/mL). The
outgrowing B cells (CD40 Bs) were restimulated every 3-4
days.
CD40 Bs were irradiated (30Gy), incubated with peptide
(5μg/mL) in serum-free IMDM for 1 hour at 37◦C, and
washed to remove excess of peptide. Then the CD40 Bs were
added to puriﬁed CD3+ autologous T cells at a ratio of 4 :
1 (T:CD40 Bs) in T cell medium (IMDM containing 10%
FCS, 2 mmol/l glutamine, and antibiotics), supplements
(1 : 100), and IL-7 (10IU/mL). T cells were restimulated
every 7 days; IL-7 was replaced by IL-2 (100IU/mL) on
day 28.
2.3. Cloning of FSP11-Speciﬁc Cytotoxic T Lymphocytes
(CTLs). Cloning of FSP11-speciﬁc T cells was performed
by limiting dilution of the T cell bulk culture. Brieﬂy,
0.7cells/well were plated in V-bottomed 96-well plates.
Lethally irradiated (30Gy) FSP11-loaded CD40 Bs of the
autologous donor ( 2 × 104/well) were added to the diluted
T cells in a ﬁnal volume of 200μl IMDM containing 10%
FCS, supplements (1 : 100) and IL-2 (100IU/mL). This
treatment was repeated weekly for restimulation. After 4
weeks,outgrowingcloneswerescreenedforspeciﬁccytotoxic
activity in IFN-γ-ELISpot and subsequently in FACSotox
Assays.
2.4. IFN-γ-ELISpot Assay. ELISpot assays were performed
using nitrocellulose-96-well plates (Multiscreen; Millipore,
Bedford, MA) covered with mouse antihuman IFN-γ mAb
(Mabtech, Nach, Sweden) and blocked with FCS-containing
medium. T cells (1 × 103) were plated in sixplicate with
1 × 104 T2 or CD40 Bs as targets in 200μlIMDM with
10% FCS. Peptides were added at a ﬁnal concentration of
10μg/mL. After incubation for 16 hours at 37◦C, plates were
washed and incubated with biotinylated rabbit-antihuman
IFNγ mAb for 4 hours, washed again and incubated with
streptavidin-coupled alkaline phosphatase followed by a
ﬁnal wash. For spot detection the plate was incubated
with NBT/BCIP (Promega, Madison, WI). The reaction was
stopped after 45–60 minutes by washing the plate with water.
The spots were counted after drying. The deduced frequency
of peptide-speciﬁc T cells was calculated by substracting
the mean number of spots in the neopeptide control from
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sample. Occasionally, resulting values were negative; those
were scored as zero.
To conﬁrm HLA-A0201 restriction of the FSP11-speciﬁc
T cells, antibody-blocking ELISpots were performed. FSP11-
pulsed CD40 Bs were incubated with the monoclonal
antibodies anti-HLA-A2 (clone BB7.2) and pan-anti-MHCI
(clone W6/32) and T cells with anti-CD3 (clone OKT3) and
anti-CD8 (clone OKT8). Irrelevant IgG2 antibody served as
a control (Immunotools, Friesoythe, Germany).
2.5. FACSotox Cytotoxicity Assay. Target cells (1 × 106;
CD40 Bs, T2, tumor cells) were stained with 5μMC F S Ei n
1mL of medium followed by an incubation at 37◦Cf o r4 5
minutes. The cells were washed twice and resuspended in
1ml medium followed by 30 minutes incubation at 37◦C.
For peptide loading, target cells were incubated with peptide
(5μg/mL) in medium without FCS for one hour at 37◦C.
CD40 Bs, T2, and tumor cells were seeded into 96-well plates
(10000cells/well). T cells were added at diﬀerent eﬀector to
target (E : T) cell ratios (1 : 5, 1 : 10, 1 : 20). For estimation
ofbackground,wellscontainingtargetcellswererunwithout
the addition of T cells. The plates were incubated at 37◦C
for 6 and 12 hours before assessment of cytotoxicity by ﬂow
cytometry. Prior to analysis, 15μg/mL propidium iodide was
addedasalive/deadstain.Thepercentageofspeciﬁclysiswas
calculated as follows:
cytotoxicity (%): [100% × dead target cells in experi-
mental sample/(dead target cells in experimental sample +
live target cells in experimental sample)] − [100% × dead
target cells in target cell control/(dead target cells in target
cell control + live target cells in target cell control)].
To further conﬁrm peptide speciﬁcity, unstained CD40
Bs loaded with FSP11 or an irrelevant peptide, respectively,
were added into some experiments. The ratio of unstained to
stained targets was 20 : 1.
2.6. Flow Cytometric Analyses. I no r d e rt oc h a r a c t e r i z eT
cell surface marker expression 3 × 105 T ,c e l l sw e r ew a s h e d
in PBS and stained with the following directly FITC or PE
labeledantibodies:CD3(cloneUCHT-1),CD8(cloneMEM-
31), CD45RO (clone UCHL1), CD50 (clone MEM-171),
CD62L (clone LT-TD180), and CD102 (clone SM223F) for
30 minutes on ice. Cells were then washed twice in PBS and
resuspended in PBS containing 1% paraformaldehyde.
Cells stained with isotype controls were used as negative
controls. Antibodies were obtained from Immunotools or
Acris (Herford, Germany). Intensities were analyzed with a
FACScalibur ﬂow cytometer (BD Biosciences).
2.7. Fragment Length Analysis. Genomic DNA was isolated
from cell lines according to standard protocols. PCR was
performedasdescribed[23].PCRprimersforU79260(FTO)
were sense TTTgTTATATCCCATTAggTgCC and antisense
AgCCTggTgACAgAgTgAgAC yielding a PCR product of
about 130 nucleotides in length. Products were separated
on an ABI3100 device (Perkin Elmer, Waltham, MA). As wt
control, gDNA from PBMCs of a healthy donor was included
into the analysis.
2.8. Statistics. All values are expressed as mean (SEM).
Student’s t-test was used to evaluate the diﬀerences between
two measurements. The criterion for signiﬁcance was taken
to be P = .05 or lower.
3. Results and Discussion
U79260(FTO) is likely to be involved in colorectal carcino-
genesis as there is an obvious positive selection pressure
towards high mutation rates in colon carcinomas (81.8%)
when compared to normal tissue and especially to other
MSI-H tumor entities (mutation rates of 6.7% in stomach
and 41.7% in endometrial carcinomas, in [8] and summa-
rized in [23]).
So far, we and others have shown that peptides derived
from frameshift mutations in genes coding for TGF-betaIIR
[15, 16], O-GlcNac transferase (OGT) [18], and Caspase-
5[ 19]g a v er i s et oC T Lc a p a b l et ol y s eM S I - Hc a n c e r
cell lines expressing these frameshift mutations. Meanwhile,
the immunogenic character of MSI-H-induced frameshift
mutations has been corroborated. Saeterdahl et al. identiﬁed
an MHC-class-II-restricted T helper epitope and Ishikawa et
al. demonstrated the existence of speciﬁc antibodies directed
against a frameshifted cMS target gene [17, 24].
Only recently, we analyzed peripheral T cell reactivity
towards several FSPs of patients with present MSI-H col-
orectal carcinoma and of HNPCC mutation carriers without
a history of tumor development [21]. A peptide mixture
covering U79260(FTO) (−1) was speciﬁcally recognized by
peripheral T cells of 25% of patients (8/32) and of 31%
of healthy mutation carriers (5/16). Additionally, reactivity
could also be observed in two out of three in vitro expanded
tumor inﬁltrating T cell populations derived from MSI-H
tumor lesions [21]. However, formal proof of antitumoral
(killing) activity of FSP-speciﬁc T cells was not provided in
that study.
3.1. Generation of FSP11-Speciﬁc Cytotoxic T Cells. In order
to analyze the immunogenic potential of the HLA-A0201-
restricted peptide FSP11 derived from a (−1) mutation of a
T(15) tract within the U79260(FTO) gene, we generated a T
cell bulk culture from an HLA-0201(pos) donor. Previously,
we could demonstrate that FSP11 was able to stabilize HLA-
A0201 molecules in a T2 stabilization assay, thus conﬁrm-
ing HLA-A0201 binding properties [15]. As for antigen-
presenting cells, we used CD40-activated B cells (CD40 Bs)
from the autologous blood donor taking advantage of the
CD40L culturesystem[15].TheseCD40Bsw e r eload edwith
FSP11 and used for repetitive stimulation of autologous T
cells. After 28 days in culture the number of T cells had
increased 5.6-fold. Stimulation was continued for more than
100 days and resulted in a T cell expansion exceeding 1000-
fold (data not shown).
Phenotypic characterization of stimulated cells by ﬂow
cytometric analysis conﬁrmed that the bulk culture nearly
exclusively contained T cells with cytotoxic potential (CD3:
99.9% and CD8: 99.0% at day 77 of culture; see Table 1). A
large part of the T cell population expressed the intercellular4 Journal of Biomedicine and Biotechnology
Table 1: Flow cytometric analysis of cell surface markers of FSP11-
speciﬁcTcells.ExpressionofseveralcellsurfacemarkersoftheFSP-
speciﬁc T cell bulk culture was analyzed on day 91 of culture by
FACS. Given is the percentage of positive cells. The corresponding
isotype controls were always under 2.5%.
Antigen Positive cells (%)
CD3 99.9
CD4 0.8
CD8 99.0
CD45RA 27.0
CD45RO 60.4
CD50 97.6
CD54 61.5
CD62L 29.4
CD102 56.6
0 1 02 03 04 05 06 07 08 0
Spots per well
CD40
Bs
CD40Bs
MP
CD40Bs
FSP11
Figure 1: ELISpot analysis. The percentage of T cells secreting
IFN-γ in response to FSP11-loaded target cells was determined in
a series of ELISpot experiments. An exemplary sample is shown.
Reactivity against unloaded, irrelevant MP-peptide-loaded and
FSP11-loaded CD40 Bs is displayed. Analysis was performed in
triplicates with 1000 eﬀector cells per well.
adhesion molecules CD50 (97.6%), CD54 (61.5%), and
CD102 (56.6%); a smaller fraction showed expression of the
activation markers CD45RO (60.4%) and CD62L (29.4%;
see Table 1). Considering the 27.0% expression of CD45RA,
these data imply that the bulk culture contains both central
and eﬀector memory T cells.
Speciﬁcity of FSP11 recognition could readily be demon-
strated in IFN-γ-ELISpot analysis. Here, the number of IFN-
γ-secreting T cells was determined upon stimulation with
HLA-A0201-positive target cells loaded with cognate and
control peptides, respectively. Approximately 5.5% of the
bulk T cells speciﬁcally secreted IFN-γ in response to FSP11-
loaded autologous B cells as target cells (Figure 1). Similar
results were also obtained using T2 cells as targets. These
results imply FSP11 speciﬁcity of the T cell bulk culture.
Additionally,therecognitioncanbeattributedtowardsHLA-
A0201 as T2 cells do not express any other HLA allele.
3.2. FSP11-Speciﬁc and HLA-A0201-Restricted Recognition of
Target Cells. Next, we analyzed the cytotoxic potential of the
FSP11-speciﬁcTcellbulk.T2aswellasBcelltargetcellswere
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Figure 2:Analysisofcytotoxicpotential oftheFSP11-speciﬁcTcell
bulk. FACSotox was performed using peptide-loaded (either FSP11
(square) or control peptide MP (diamond)) (a) T2 cells and (b)
CD40 Bs as target cells. Eﬀector bulk T cells were added at diﬀerent
eﬀector to target cell (E : T) ratios. A representative experiment of
three is shown. Analysis was performed after a 6-hour incubation
period.
selectively lysed when loaded with FSP11. Target cells loaded
with an irrelevant peptide were not recognized (Figure 2).
To formally conﬁrm FSP11 speciﬁcity and HLA-A0201
restriction,targetkillinhibitionexperimentswereperformed
by adding an excess of unstained CD40 Bs into these
experiments. Lysis of stained and FSP11-loaded CD40 Bs
was substantially inhibited by an excess of unstained target
cells loaded with FSP11 (ratio of labeled targets: unlabeled
targets = 1 : 20). In contrast, unstained CD40 Bs loaded
with the irrelevant MP peptide had much less eﬀect on target
celllysis(Figure 3).Moreover,thenumberofIFN-γ secreting
T cells in response towards FSP11 was signiﬁcantly reduced
by adding antibodies directed against pan MHC-class-I or
against HLA-A0201 into ELISpot analysis (Figure 4).
In summary, these data reliably demonstrate speciﬁc
recognition of FSP11 by the bulk T cells in the context
of HLA-A0201. Additionally, antibodies directed towards
cytotoxic T cells (CD3 and CD8) also signiﬁcantly blocked
the recognition (Figure 4).
3.3. Lysis of Colorectal Carcinoma Cells Endogenously Express-
ing U79260(FTO) (−1). Woerner et al. described that most
MSI-H colorectal tumor cell lines (6/11) carry (−1) or
(−4)mutationsofU79260(FTO)[23].Toeliminatepotential
mistakes originating from expression of diﬀerent mutationsJournal of Biomedicine and Biotechnology 5
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Figure 3: Target inhibition. FSP11 speciﬁcity and HLA-A0201
r e s t r i c t i o no ft a r g e tc e l ll y s i so fFSP11-speciﬁc T cells were tested
at two diﬀerent E : T cell ratios (10 : 1, 30 : 1) in the presence
of an excess of unlabeled target cells (CD40 Bs pulsed with either
FSP11 (square) or control peptide MP (diamond)) at an unlabeled:
labeled target cell ratio of 20 : 1). Displayed is the percentage of
labeled and FSP11-loaded CD40 Bs killed by the FSP11-speciﬁc T
cells. A representative experiment of three is shown. Analysis was
performed after a 6-hour incubation period.
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Figure 4: Antibody-blocking ELISpot analysis. FSP11 recognition
of FSP11-speciﬁc T cells could be blocked by antibodies towards
HLA(pan), HLA-A0201, CD3, and CD8 but not by IgG2 control
antibody. The reactivity without the addition of antibodies is given
as positive control. T2 cells loaded with FSP11 were used as targets.
Either T2 cells or T cells were preincubated with antibodies towards
HLA(pan) and HLA-A0201 (T2) or CD3 and CD8 (T cells) for one
hour prior to setup of the ELISpot.
and wt forms of U79260(FTO) in diﬀerent batches of MSI-H
cell lines, the batches used in the current set of experiments
were analyzed by fragment length analysis (data not shown).
Although speciﬁcity and cytotoxic potential of the bulk
T cells have been shown, the most important feature
in the context of antitumoral activity is the ability to
recognize tumor cells expressing the underlying mutation
endogenously. The FSP11 speciﬁc bulk culture speciﬁcally
recognized the MSI-H, HLA-0201(pos) colon carcinoma line
HCT116, which endogenously expresses a (−4)-mutated
form of U79260(FTO) corresponding to the (−1) frame
coding for FSP11 (Figure 5(a)). Contrary to that, there was
neither signiﬁcant recognition of the HLA-A0201(neg) cell
line KM12, which expresses a (−4) version of U79260(FTO),
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Figure 5: FSP11-speciﬁc T cells recognize tumor cell targets.
T cell reactivity of the FSP11-speciﬁc (a) T cell bulk and (b)
T cell clone C10/11 towards diﬀerent tumor cell targets was
tested at an eﬀector to target (E : T) cell ratio of 20 :
1. Targets tested were Colo60H, HLA-0201(pos)/ U79260(FTO)
(−3); HCT116, HLA-0201(pos)/U79260(FTO) (−4); SW480: HLA-
0201(pos)/U79260(FTO) (wt) with and without addition of FSP11;
and KM12: HLA-0201(neg)/U79260(FTO) (−4). A representative
experiment of three is shown. Analysis was performed after a 12-
hour incubation period.
nor of the HLA-A0201(pos) SW480 cells. However, SW480 is
recognized when FSP11 is added exogenously (Figure 5(a)).
Comparable results were obtained using a CTL clone
(C10/11) generated from the FSP11 bulk T cell culture
by limiting dilution. At an eﬀector to target cell ratio of
5 : 1, HCT116 cells (HLA-A0201(pos); U79260(FTO) (−4))
were eﬀectively killed, whereas SW480 (HLA-A0201(pos);
U79260(FTO) (wt)) and Colo60H (HLA-A0201(pos);
U79260(FTO) (−3)) control cells were relatively unaﬀected
(Figure 5(b)).
4. Conclusions
In the present study, we identify a novel MHC-class-I-
restricted CTL epitope derived from U79260(FTO).T h e
peptide FSP11 (TLSPGWSAV) sensitized peripheral CD8+
T cells of a healthy donor for speciﬁc release of IFN-γ
and mediated recognition in the context of HLA-A0201.
The obtained T cell cultures were able to selectively attack
tumor cells expressing the underlying mutation together
with HLA-A0201. Remarkably, these results additionally
imply that U79260(FTO) must be expressed and translated
intoatruncatedproteinthatissubsequentlyprocessedbythe
cellular proteasomal machinery and presented in the context
of MHC molecules.6 Journal of Biomedicine and Biotechnology
Generally, MSI-H-induced FSPs represent an outstand-
ing class of tumor-speciﬁc antigens that may prove suitable
for future clinical applications. Beside immunotherapeutic
interventions for patients suﬀering from an MSI-H tumor,
this even opens up the remarkable possibility of prophylactic
vaccinations for HNPCC mutation carriers.
Abbreviations
CD40 Bs: CD40-activated B cells
CTL: Cytotoxic T lymphocyte
ELISpot: Enzyme-linked immunospot
E:Tr a t i o :E ﬀector : target cell ratio
FACSotox: Fluorescence-activated cell-sorting-based
cytotoxicity assay
FSP: Frameshift peptide
HLA: Human leucocyte antigen
MHC: Major histocompatibility complex
MMR: Mismatch repair system
MSI-H: (High level) Microsatellite instability.
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